Sample size and power for the weighted log‐rank test and Kaplan‐Meier based tests with allowance for nonproportional hazards

Design and monitoring of survival trials in complex scenarios

(2018) Xiaodong Luo et al.   STATISTICS IN MEDICINE

End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma

(2017) Antje Hoering et al.   Future Oncology

Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio

(2017) Kyongsun Pak et al.   JAMA Oncology

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

On the restricted mean survival time curve in survival analysis

(2015) Lihui Zhao et al.   BIOMETRICS

Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors

(2015) Tai-Tsang Chen   JNCI-Journal of the National Cancer Institute

Milestone Survival: A Potential Intermediate Endpoint for Immune Checkpoint Inhibitors

(2015) Tai-Tsang Chen   JNCI-Journal of the National Cancer Institute

Moving Beyond the Hazard Ratio in Quantifying the Between-Group Difference in Survival Analysis

(2014) Hajime Uno et al.   JOURNAL OF CLINICAL ONCOLOGY

Sample size determination for the weighted log-rank test with the Fleming-Harrington class of weights in cancer vaccine studies

(2014) Takahiro Hasegawa   PHARMACEUTICAL STATISTICS

Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome

(2013) Patrick Royston et al.   BMC Medical Research Methodology

Sample size calculation for the proportional hazards cure model

(2012) Songfeng Wang et al.   STATISTICS IN MEDICINE